Redcare Pharmacy N.V. has increased its full-year 2026 revenue guidance for the second time this year, citing stronger-than-expected growth in prescription (Rx) revenue in Germany. The Netherlands-based online pharmacy now expects Rx revenue in Germany to reach EUR 730 million to EUR 760 million for the full year, up from a previous range of EUR 680 million to EUR 720 million. That revised outlook implies growth of 45% to 51%, compared with the earlier forecast of 35% to 43%.
The upgrade follows preliminary figures showing that Rx revenue in Germany grew by 51% year-on-year in September and by 56% in the third quarter. September’s performance came despite a high comparison base from the prior year, when the current Rx bonus was introduced. The company said it will publish the complete set of third-quarter 2026 figures on October 29, 2026.
“Our growth is backed by strong customer satisfaction: eRx NPS continues to rise, up 6 points year-on-year to 80 in August,” said Olaf Heinrich, CEO of Redcare Pharmacy. The rising Net Promoter Score suggests that customers are not only using the service but also recommending it, a key indicator of sustainable growth in a competitive online pharmacy market.
While Rx revenue remained robust throughout the quarter, non-Rx revenue in Germany rebounded well in August and September after a softer July. Based on preliminary figures, the adjusted EBITDA margin remained flat quarter-on-quarter, benefiting from continued operating leverage. The company’s full-year 2026 guidance now stands as follows: total revenue growth of 16% to 18%, up from the previous 15% to 17%; non-Rx growth unchanged at 10% to 12%; Rx revenue in Germany of EUR 730 million to EUR 760 million; and an adjusted EBITDA margin confirmed at 2.5% to 3.0%.
The guidance raise matters for investors and the broader digital health sector because it demonstrates that online pharmacy platforms can scale prescription volumes profitably even as they face regulatory and competitive pressures. Redcare Pharmacy, which generated EUR 2.9 billion in revenues in 2025, serves more than 14 million active customers across seven European countries: Germany, Austria, France, Belgium, Italy, the Netherlands, and Switzerland. It offers over 500,000 healthcare-related products, including over-the-counter drugs, nutritional supplements, beauty and personal care items, and prescription drugs in Germany, Switzerland, and the Netherlands.
Listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and a member of the SDAX, Redcare Pharmacy will host its quarterly conference call on October 29, 2026, alongside the release of its Interim Statement for the third quarter of 2026. The company also plans to publish its Annual Report 2026 on March 4, 2027. The original release can be viewed via www.newmediawire.com.
For readers, the announcement signals that digital prescription fulfillment is gaining mainstream traction in Europe’s largest healthcare market. For the industry, it underscores the growing role of online pharmacies in improving access to medications and may encourage further investment in e-pharmacy infrastructure. As Redcare Pharmacy continues to benefit from operating leverage, its ability to maintain margin guidance while accelerating revenue growth could set a benchmark for competitors across the continent.
